Search Medical Condition
Please enter condition
Please choose location from dropdown

Lince, Peru Clinical Trials

A listing of Lince, Peru clinical trials actively recruiting patients volunteers.

Found (72) clinical trials

Early CPAP in Respiratory Distress Syndrome

The application of CPAP has been described as an alternative respiratory support for premature newborns with respiratory distress.Many studies support that the early use of CPAP results in a better respiratory evolution and less need for mechanical ventilation. Hypothesis: - The hypothesis is that EBCPAP will decrease the need for …

Phase

2.73 miles

Learn More »

Study of ARQ 092 in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC)

This is an open label, Phase 1/2 study of ARQ 092 (Miransertib) administered orally. The study consists of two parts: Part A and Part B. Part A is now closed to enrollment. The study objectives for Part A are: To assess the safety and tolerability of ARQ 092 in patients …

Phase

2.73 miles

Learn More »

Evaluation of a Diagnostic Device CL Detect Rapid Test for the Diagnosis of Cutaneous Leishmaniasis in Peru

Observational study of a FDA cleared device, the CL Detect Rapid Test. Data for the 510(K) was supported by a sensitivity study conducted in Tunisia, Old world Leishamania major and a specificity study conducted in the United Sates. Sensitivity and specificity data collected recently in Peru (2014-2015), by the Instituto …

Phase N/A

2.73 miles

Learn More »

Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use

Specific Aims: Recent studies suggest that very early initiation of ART (prior to seroconversion) does not prevent the establishment of HIV reservoirs, which eventually expand when ART is discontinued (1, 2). Early ART initiation is, however, associated with preservation of CD4+ T cells and lower levels of total HIV DNA …

Phase N/A

2.73 miles

Learn More »

A Study of Immune Responses to the Virus That Causes COVID-19

This is a prospective study of acute immune responses to SARSCoV-2 infection. The study will include 3 groups, as described in the table below. Groups are defined based on clinical status at enrollment, but for the purposes of data analysis, participants who experience disease progression can contribute data to other …

Phase N/A

2.73 miles

Learn More »

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Women will be randomized in a 1:1 ratio to receive treatment with concurrent durvalumab + standard of care (SoC) or Placebo + Soc, followed by durvalumab/placebo maintenance for 24 months.

Phase

2.73 miles

Learn More »

Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology

The CAUSE study is a multicenter study, with domestic (n=4) and international (n=6) study sites. Children and young adults (ages 0-18) who have microtia and/or craniofacial microsomia and their parents are invited to participate. Children and parents are asked to provide a DNA sample (blood or saliva) and are asked …

Phase N/A

2.73 miles

Learn More »

Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis

PandrTB is an observational study nested in the endTB trial, a randomized study that will evaluate five 9-month, injectable-sparing regimens that could transform the treatment of MDR-TB. As part of PandrTB: the plasma concentrations of the experimental arm drugs (the new and repurposed drugs bedaquiline, delamanid, clofazimine and linezolid, as …

Phase N/A

2.73 miles

Learn More »

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind study in patients with HFpEF, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death and heart failure …

Phase

3.33 miles

Learn More »

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+ HER2- Advanced Breast Cancer

QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib (Kisqali Prescribing Information, Investigator Brochure). The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whether a reduced dosing …

Phase

3.33 miles

Learn More »